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Background: Recruitment and inclusion procedures in clinical trials are time critical. This
holds particularly true for studies investigating patients with fluctuating symptom patterns,
like those with chronic neck pain. In a feasibility study on neck pain, we found a clinically
relevant decrease in pain ratings within the recruitment period. This paper analyses the
phenomenon and gives recommendations for recruitment procedures in clinical trials on pain.
Methods: Changes in pain intensity scores of 44 chronic neck pain patients (6 males and 36
females; mean age: 45.3±13.2 years) between the first telephone contact and baseline
assessment were analyzed. Inclusion criterion was a mean pain intensity of ≥40 on a 0–
100 numerical rating scale during the last three months. Statistical analyses were performed
using ANOVA and parametric/non-parametric correlation coefficients.
Results: Average pain intensity score decreased significantly from 60.3±13.3 at telephone
interview to 38.1±21.7 at baseline assessment. This represents a relative change of 36.8%. A
weak but significant negative correlation was found between number of days between
assessments and pain rating differences. There was a positive correlation between change
of pain intensity and the pain level at the first contact, indicating that the decreased pain
ratings over time were also dependent on the initial pain rating.
Conclusions: The clinically significant changes in pain intensity were weakly related to
waiting time and moderately dependent on initial pain intensity, suggesting regression to the
mean. The natural course of the disease and the Hawthorne effect are also discussed as
contributing factors.
Keywords: chronic neck pain, Hawthorne effect, natural course of the disease, regression to
the mean, clinical trial, recruitment
Introduction
Recruitment describes the selection process of participants/patients into a clinical
trial, from the first communication to their enrolment, and is one of the most essential
components in clinical research. A recruitment process can be complicated and time
consuming, depending on the nature of the disease, the character of the inclusion/
exclusion criteria, the type of intervention (single subject or group therapy), and the
necessary procedures to check for those.
Complicated and time-consuming recruitment procedures are possibly acceptable for
patients suffering from chronic diseases with a relatively stable time course of symptoms,
but challenging for a clinical study recruiting patients suffering from pain syndromes
with fluctuating symptom patterns such as musculoskeletal pain disorders. In diseases
and syndromes with fluctuating pain, one might observe changes in pain ratings from
inclusion to baseline which may obscure a potential treatment effect and contribute to
high or early drop-out rates.
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Generally, patients with fluctuating symptom patterns
are usually contacted for participating in a potential study
at times when the symptoms are particularly severe. If
inclusion requires a time-consuming recruitment process,
patients may experience reduced symptom severity at the
time of enrolment, which will obscure the potential effect
of the intervention investigated (“little or no pain – little or
no gain”). In worst case, they may not fit the inclusion
criteria anymore by the time the intervention begins.
Thus, the natural course of a disorder or a disease may
play a significant role in clinical trials, even though it may be
difficult to estimate its impact.1–3 Only a few clinical trials
provide a consistent report of the time period from the first
communication with the study participant, baseline assess-
ment, and details of the time course of the symptoms.
Performing a feasibility pilot study as a first step can help
to identify and avoid threats to the implementation of a larger
trial.4,5 In a feasibility study on neck pain, our study group
encountered a substantial decrease of pain intensity, between
the telephone interview, as a first contact and the enrolment
into the study. This change in pain ratings due to study routines
and time schedule is relevant and can impose a threat to the
main study itself.6–12
Therefore, the aim of this paper is to analyze the phenom-
enon of a clinically significant pain reduction after inclusion
but before the beginning of the intervention and to investigate
the contributing factors in order to avoid this phenomenon in
larger trials on chronic non-specific neck pain.
Methods
General remarks
The data presented here are a part of a feasibility study,
“Chronic, non-specific neck pain. Quantitative Sensory
Testing (QST) as a tool for the investigation of massage
and relaxation as interventions - a feasibility study” which
aimed to explore study routines to prepare a clinical trial
comparing clinical effects of massage and meditation as
treatment interventions for chronic, non-specific neck pain
including quantitative sensory testing as a biomarker.
Although some details of the feasibility study are presented,
our analyses will focus on the change in pain ratings during
recruitment or the time period from the first contact to base-
line assessment, just prior to the intervention.
Study participants
Study participants were recruited through local newspaper
advertisements. During a telephone interview performed
by one single person, they were screened for inclusion and
exclusion criteria before referral to physical examination
by a physician (A.J.N.).
Inclusion criteria were age between 21 and 75 years and
non-specific neck pain persisting at least 3 months with a
mean pain intensity of greater than or equal to 40 on a 100-
point numerical rating scale (NRS, 0= “no pain at all”, 100=
“worst pain imaginable”). The patients were excluded if they
suffered from a congenital deformation of the spine or had
neurological symptoms, neuropathic pain, spine surgery less
than 12months prior to screening, or received transcutaneous
electrical nerve stimulation (TENS), acupuncture, osteopa-
thy, chiropractic maneuver, or infiltration in the area within 4
weeks prior to inclusion.With regard tomedications, patients
were excluded if they needed to take blood-thinning medi-
cine, steroids, or strong pain medications, such as opioids.
Patients were allowed to continue to use non-steroidal anti-
inflammatory drugs (NSAID), if that was part of their current
pain management. The use of medications was documented
in a pain diary throughout the study.
The study was approved by the regional ethics com-
mittee (Regional committees for medical and health
research ethics, REC North 2014/1105). Participants were
informed about the purpose of the study, risk/benefit pro-
file of the interventions and the study itself. All partici-
pants were free to withdraw from participation at any point
if they wished to. All participants provided written
informed consent prior to participation. The study was
performed in accordance with the declaration of Helsinki.
Design
Figure 1 shows the study design of the feasibility study.
After verification of eligibility of the study participants in
telephone interview (T0) and screening by study doctor,
participants were included in the study. The study had a
parallel design with two intervention arms; massage and
relaxation. After baseline assessment (T1), patients received
five treatment sessions of either massage or relaxation,
followed by post-intervention assessment (T2), and fol-
low-up assessment (T3) 4 weeks later.
The analysis presented here focuses on the change of
pain intensity indicated by study participants from the
telephone interview (T0) to the baseline assessment (T1),
before randomization into two study groups.
Primary outcome was the change of pain intensity. Pain
intensity was recorded at all 4 assessments (T0, T1, T2, and T3)
using the numerical rating scale (NRS, 0–100) at T0 and the
visual analog scale (VAS, 0–100) at T1, T2, and T3. As
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secondary outcome, we performed a Quantitative Sensory
Testing (QST) according to the standardized protocol estab-
lishing by the German Research Network onNeuropathic Pain




The analyses of the data presented in this paper focus on the
differences of pain ratings given by the study participants
between the telephone interview (T0) and the baseline assess-
ment (T1). Pain intensity assessed during the telephone inter-
view (T0) was recorded on a numerical rating scale (NRS)
graded from 0 to 100 (0= “no pain at all”, 100= “worst pain
imaginable”). Pain intensity assessed at baseline assessment
prior to randomization (T1) was recorded on a visual analog
scale (VAS) graded from 0 mm to 100 mm (0 mm = “no pain
at all”, 100 mm = “worst pain imaginable”). Both, NRS and
VAS scores were transferred in a common 0–100 pain rating
scale to compare the pain ratings at both time points.
Expectation
Within the feasibility study, expectations regarding the
anticipated treatment effects were measured at baseline
assessment (T1). The patients self-rated their expectations
about the intervention on a VAS ranging from 0 mm to 100
mm (0 mm = “not effective at all”, 100 mm = “highly
effective”) at the baseline assessment (T1). Since expecta-
tions are seen as a part of a potential placebo effect within
an interventional study, they are likewise relevant for the
analyses presented in this paper.14–16
Statistical methods
Data for age, weight, height, BMI, pain intensity, and number
of days between telephone interview (T0) and baseline
assessment (T1) are presented as means with standard devia-
tion (SD) and 95% confidence interval (95%CI of mean).We
used Student T-test for paired samples to calculate the differ-
ence in pain intensity at T0 and T1. Normal distribution was
tested using the Kolmogorov–Smirnov test.
For the statistical analyses of the change in pain
intensity over time, the whole sample was further
divided into two subgroups with regard to waiting
time, ie, days between T0 and T1; group A: 1–14 days
and group B: >14 days, based on a common waiting
time after inclusion of about two weeks in clinical trials.
The differences of pain ratings were analyzed with ana-
lysis of variance (ANOVA) using the differences of pain
ratings between T0 and T1 as the within-subject factor
and the grouping in two groups according to the days
between the T0 and T1 as the between-subject factors.
The pain rating (NRS 0–100) at T0 was set as covariate
in this model. No post hoc test was performed, since
only two groups were compared.
Finally, three correlation analyses were performed to
investigate a) the relationship between number of days
between T0 and T1 and change in pain ratings, with the
aim to identify a possible dependence on waiting time
potentially related to the natural course of the disease,
and b) the relationship between change in pain ratings
between T0 and T1 and pain rating level at T0, to identify
regression to the mean, and c) the relationship between the
difference of pain ratings between T0 and T1 and the
expectation (0–100) about treatment effects at T1, in
order to investigate the impact of patient’s expectations
which may play a role as part of a placebo effect.
Correlation analyses were conducted using Pearson’s pro-
duct–moment correlation coefficient for normally distrib-
uted parameters, and Kendall’s Tau correlation coefficient
Figure 1 Study design of feasibility study across all assessments (T0, T1, T2, and T3). The analysis in the current study focuses on the time interval between the telephone
interview (T0) and the baseline assessment (T1) presenting the gray structured square. The randomization into the groups (massage and relaxation) was performed after the
baseline assessment (T1).
Abbreviations: T0, telephone interview; T1, baseline assessment; T2, post-intervention assessment; T3, follow-up assessment.
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for non-normally distributed parameters. Correlation coef-
ficients were interpreted as follows: |r| ≤0.29=negligible,
0.30–0.49=low, 0.50–0.69=moderate, 0.70–0.89 high, and
>0.90=very high.
A p-value of <0.05 was considered statistically sig-
nificant. Statistical analyses were performed using




A total of 85 potential patients were screened for eligibil-
ity by telephone interview (T0), of these 51 were invited to
the screening by the study physician (A.J.N.). A total of 44
patients fulfilled the inclusion criteria and agreed to parti-
cipate in the study. The reasons for exclusion were pain
intensity below 40 on a 0–100 pain rating scale at the time
point of the clinical investigation (N=11), the localization
of pain apart from the neck (N=6), and other ongoing, non-
pharmacological treatments (N=2).
All patients underwent baseline assessment at (T1).
Two patients were considered as outlier according to wait-
ing time between T0 and T1 and excluded from the statis-
tical analyses. The outliers were defined as the values that
were more than 1.5 x interquartile range beyond the 25th
and 75th percentiles.17
Figure 2 shows a flow chart of patient flow throughout
the feasibility study. The time points analyzed to deter-
mine possible changes in pain ratings during recruitment
and inclusion are marked in black.
Sample characteristics
A total of 42 neck pain patients (45.3±13.2 years,mean±SD), 6
males and 36 females, were included in the statistical analyses.
Average pain intensity and SD at T0 was 60.3±13.3 and at T1
38.1±21.7. The average time betweenT0 andT1was 18.7±11.1
days. The expectation of the patients regarding the anticipated
effectiveness of the treatment was 69.2±19.5 on a 0–100 VAS.
Table 1 shows the demographic and clinical characteristics for
the total sample.
Assessed for eligibility (N=87)
Excluded (N=2)
Excluded (N=25)
. No neck pain (N=6)
. Pain ≤ 40 on NRS 0-100 (N=11)
. Pain syndrome too complex (N=2)
. Pain syndrome acute, not chronic (N=1)
.Other non-pharmacological treatment (N=2)
.Other (N=3)
.Declined to participate (N=9)
.Declined to participate (N=5)
Excluded (N=2)
Screening by study doctor (N=51)
Analyzed (N=42)
Excluded from analysis (N=2)
. Not eligible
. Taking opioids
Baseline assessment (N=44), T1
Screening by telephone (N=85), T0
Figure 2 Flow chart of recruitment and progress of patients through study (the whole flow chart, gray). The analysis of the pain ratings during recruitment is based on pain
intensity from the screening interview by telephone (T0) and baseline assessment (T1) (marked black in the flow chart).
Abbreviations: T0, telephone interview; T1, baseline assessment.
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Analyses of the pain ratings during
recruitment and inclusion
Time course
Of thewhole sample (N=42), 34 participants showed a decrease
in pain rating from T0 to T1. This was the case for all partici-
pants (N=20) whowaited 1–14 days and for 14 out of 22 with a
waiting time >14 days (N=22). Only 6 patients reported an
increased pain intensity, while 2 patients reported similar values
at T0 and T1 (see Figure 3). Figure 3 reveals that 24 participants
exhibited a pain score of <40 at T1 and were thus not fulfilling
the main inclusion criterion to the feasibility study.
The average pain intensity at T0 was 60.3±13.3 (0–100,
mean±SD) and at T1 38.1±21.7 (0–100, mean±SD). The
difference in pain intensity between T0 and T1 corre-
sponded 36.8% of the value at T0.
The analysis of variance (ANOVA) for the pain ratings
on T0 and T1 showed a significant main effect of the factor;
days between T0 and T1 (F(1,39)=6.17; p=0.017; ε=0.14).
Furthermore, we found a significant effect for the covariate
pain rating (NRS, 0–100) at T0 (F(1,39)=14.14; p=0.001;
ε=0.27), indicating that the decrease in pain ratings over
time was partly dependent on the initial pain rating at T0.
Correlation of the change in pain scores and the
initial pain scores at T0
In order to further investigate the covariate pain rating at
T0, we conducted an additional correlation analysis includ-
ing the change in pain ratings from T0 to T1 and the pain
level at T0. The analysis revealed a significant, although
moderate positive correlation (r=0.52; p<0.001) supporting
Table 1 Demographic and clinical characteristics of the total sample being analyzed
Total
N=42
Gender, N Male/female 6/36
Age, years,a Mean±SD








(95% CI of mean)
168.1±7.5
(165.7–170.4)
Body mass index, kg/m2,a Mean±SD
(95% CI of mean)
27.1±4.0
(25.9–28.3)
Pain intensity (NRS, 0–100) Telephone interview (T0),
a Mean±SD
(95% CI of mean)
60.3±13.3
(56.2–64.4)
Pain intensity (VAS, 0–100) Baseline assessment (T1),
a Mean±SD
(95% CI of mean)
38.1±21.7
(31.4–44.9)
Difference of pain intensity (0–100, T0-T1),
a Mean±SD







Pain medication (NSAID), N
Baseline assessment (T1)
Male/female 1/9
Days between Telephone interview (T0) and Baseline assessment (T1) Mean±SD







(95% CI of mean)
69.2±19.5
(63.2–75.3)
Notes: Data are presented as mean±SD (95% CI of mean). aNormal distribution parameter by using the Kolmogorov–Smirnov test. NRS, 0–100 (0= "no pain", 100= "worst
pain imaginable"); VAS, 0–100 (0= "no pain", 100= "worst pain imaginable").
Abbreviations: N, number of participants; SD, standard deviation; NRS, numerical rating scale; VAS, visual analog scale; NSAID, non-steroidal anti-inflammatory drugs.
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the findings from the regression analysis above that the
pain reduction from T0 to T1 was in part dependent on the
initial pain rating at T0 (see Figure 4).
Correlation of the change in pain scores with
absolute waiting time
If the decrease in pain ratings is dependent on waiting
time, then the difference in pain ratings between T0 and
T1 should correlate with the absolute waiting time. The
correlation analysis revealed a statistically significant
negative but negligible correlation (r = −0.25; p=0.020)
between number of days from T0 to T1 and the corre-
sponding difference in pain ratings. This indicates that
the decrease in pain ratings was not strongly dependent
on waiting time (see Figure 5).
Correlation of the change in pain
scores with expected treatment
effects (expectation) at T1
There was no significant correlation (r=−0.01; p=0.948)
between the difference of pain ratings between T0 and T1,
and the participant’ expectation (0–100) about anticipated
treatment effect (see Figure 6). Therefore, the decrease in
pain ratings was not related to expectations about effec-
tiveness of the interventions.
Discussion
The mean decrease in pain intensity from the first contact
(T0) until randomization (T1) in our study was 36.8%. This
is by definition above the cut off of 30% the minimal
clinically important difference (MCID) and equivalent to
a moderate pain reduction.6,10,12, Moreover, the effect was
rather consistent, as 34 of the total sample (N=42) revealed
a pain reduction during the waiting period.
Natural course of the disease
Neck pain fluctuates over time, and patients are probably
most willing to participate in a study when their pain is
temporarily more intense. Later, when the patient is to be
randomized the pain levels may be lower due its natural
course.2,3
The natural history of a disease describes its time course
during the absence of an intervention.1 This effect should
have a similar influence on all study groups, if they are
equally handled with regard to study procedures, and blind-
ing and randomization are successful. However, the natural
course of the disease may affect study outcomes substantially
across groups, depending on the time course of the symptoms
and the time interval between inclusion and intervention, and
thus imposes a threat to the internal validity of a study.1
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Figure 3 Course of pain ratings (0–100) between the telephone interview (T0) and baseline assessment (T1). For all patients (N=42), both pain ratings were plotted before
randomization. For the statistical analyses, the patients were classified into two groups depending on the waiting time between T0 and T1: group A patients with 1–14 days
between T0 and T1 (N=20), group B patients with more than 14 days between T0 and T1 (N=22). The horizontal dashed line indicates the pain intensity criterion for
inclusion into the feasibility study (greater than or equal to 40 on a 0–100 rating scale).
Abbreviations: T0, telephone interview; T1, baseline assessment.
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The significant correlation between waiting time and
change in pain rating supports at first glance the assump-
tion that a natural course of neck pain contributed to the
effect. Nonetheless, the effect is not entirely consistent
over time, as we also see less pain reduction with
increased waiting time. A closer look at Figure 4 reveals
negative values for six patients (left of the dotted vertical
line). These were the patients who waited exceptionally
long for T1 (ranged from 15 to 43 days from T0 to T1).
Thus, it is likely that these patients waited so long that
they experienced an increase in pain ratings over time.
Thus, the curve may in fact be more u-shaped as it appears
in the correlational analysis, with an initial decrease in
pain, followed by an increase over time.
Nonetheless, symptom fluctuation did not seem to be
the only reason for the moderate pain reduction during the
enrolment phase. The correlation between the change in
pain rating and the initial pain rating at T0 suggests that the
change in pain rating over time is also dependent on initial
pain intensity at T0. A fact that could support the hypoth-
esis that participants are more likely to enter a study when
their pain is particularly intense.
Regression to the mean
Another highly relevant phenomenon with regard to fluc-
tuating symptom patterns is the so-called “regression to
the mean”.18–20 Regression to the mean is a purely statis-
tical phenomenon, describing the general tendency for
extreme values to converge towards a middle level.21
The more extreme the initial value is, the higher the
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Figure 4 The scatter plot shows the relationship between pain changes from
telephone interview (T0) to baseline assessment (T1) and the pain rating at T0.
For each patient (N=42), the change in pain rating (x-axis) is plotted against the pain
level at T0 (y-axis). The vertical dashed line represents a difference in pain rating of
0. Data points on the right illustrate patients with a decreasing pain rating to T1,
while data points on the left illustrate patients with an increasing pain rating to T1.
Abbreviations: T0, telephone interview; T1, baseline assessment; NRS, numerical
rating scale.




























Figure 5 The scatter plot shows the relationship between waiting time until
baseline assessment and differences in the pain intensity between the two measure-
ment points. For each patient (N=42), the number of days between the telephone
interview (T0) and baseline assessment (T1) (x-axis) are plotted against the differ-
ences in pain ratings from the telephone interview (T0) and baseline assessment
(T1) (y-axis). The horizontal dashed line represents a change in pain rating (T0 - T1)
of 0. Data points above the dashed line illustrate patients with a decreasing pain
rating to T1, while data points below the dashed line illustrate patients with an
increasing pain rating to T1.
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Figure 6 The scatter plot depicts the correlation between the differences in pain
from the telephone interview (T0) to baseline assessment (T1), and the expecta-
tions of the study participants about the study outcome. For each patient (N=42),
the differences (T0-T1) for the pain ratings (x-axis) are plotted against and the
expectations at T1 (y-axis). The vertical dashed line represents the differences of
the pain ratings (T0-T1). The data points on the right illustrate patients with a
decreasing pain rating up to T1, data points on the left illustrate patients with an
increasing pain rating up to T1.
Abbreviations: T0, telephone interview; T1, baseline assessment; VAS, visual
analog scale.
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For fluctuating pain syndromes, this implies that a high
pain intensity prior to examination will to some extent, in
itself, predict the following decrease. Taken together, the
fact that it is necessary to define a reasonably high initial
value as inclusion criterion in pain trials implies that
regression to the mean is likely to occur. Regression to
the mean can affect any investigation where the response
to treatment is classified relative to initial values.23
In conclusion, both the natural course of the pain syn-
drome and regression to the mean may have influenced the
decrease in pain intensity in our study.1,24 A predefined
inclusion criterion with high pain intensity will lead to a
data structure, where regression to themean is likely to occur.
Possible placebo effects and expectation
Expectation-dependent placebo effects are an inherent part
of all clinical interventions and must be taken into account.
It is therefore a standard baseline procedure in clinical
trials to include questions about expectations about the
treatment effects. This was therefore done at T1 in the
planned feasibility study. Although we did not assess
expectation at T0, we assumed that by the fact that the
study participants showed up at T1 to enter the interven-
tional part of the study that their expectations about the
effectiveness of the treatment were at least as high at T1.
Therefore, even though the correlation between the parti-
cipant’s expectation at T1 and the difference in pain ratings
between T0 and T1 represents a “backward analysis”, it
still provides information on how expectation influenced
the difference in pain ratings.14–16
The correlation analysis revealed that there was no
influence of treatment effect related expectations on the
difference in pain ratings. Figure 6 shows the reason for
that: treatment effect expectations were uniformly high
(69.2±19.5, Table 1) at T1 so that there was not enough
variation in expectations to correlate with the change in
pain ratings. In conclusion, even though we should con-
sider expectation-dependent placebo effects as part of the
treatment effect in the feasibility study (not presented
here), we find it unlikely, that the expectation-dependent
placebo effects played a role for the reduction in pain
ratings within the waiting period.
The Hawthorne effect
Another, critical issue with regard to fluctuations in outcome
measures may be the so-called Hawthorne effect. This effect
describes the phenomenon that a person may change her or
his behavior, experiences, emotions, etc., when becoming a
study participant.25–28 The phenomenon is interpreted as a
type of reactivity to the situation, where a person is being
systematically investigated and “observed”. A possible rea-
son for this effect may be increased attention to factors that
are related to the study outcomes.
Thus, independent of the natural course of the disease,
the inclusion procedure and the enrolment into a study
may, in itself, have a major impact on the main study
outcomes. Even though this influence can be expected to
be equally distributed among the study groups,29–32 the
Hawthorne effect is difficult to control in experimental as
well as, placebo and non-treatment control groups.
Limitations
The data presented are part of the feasibility study on how to
integrate the standardized protocol of DFNS QST protocol
into a clinical trial on the effects of massage and meditation
for chronic, non-specific neck pain. However, the study was
not planned to directly assess recruitment and enrolment-
related problems. Thus, a more differentiated design,
directly aiming at possible threats to the internal validity
of outcomes in pain trials during the recruitment and enrol-
ment phase, would have been more appropriate.
Nonetheless, we assume that the challenges to a clinical
study on pain presented here are of relevance to other pain
researchers and have to be regarded in further clinical trials.
The use of two different pain rating scales in this study
is another limitation. During the screening (telephone
interview, T0), patients assessed pain intensity with a
numeric rating scale (NRS, 0–100) while a visual analog
scale (VAS, 0–100) was used at baseline assessment (T1).
The reason for this incongruence is that the NRS is easier
to handle in a telephone interview situation.
Although it has been shown that NRS and VAS ratings
correlate significantly, VAS scores have a tendency to
reveal lower ratings compared to NRS scores. Thus, it is
not unproblematic to use these two scales interchangeably
when assessing self-reported pain.33,34 In our study, the
fact that NRS scores seem to reveal higher pain ratings
than VAS scores means that the pain scores measured at T0
possibly overestimate pain compared to the VAS pain
measures at T1. Ultimately, this overestimation would
contribute to higher pain values at the first measurement
point (T0) and could thus lead to an overestimation of the
decrease in pain ratings from T0 to T1. In conclusion, it
would be important to estimate whether the decrease in
Nothnagel et al Dovepress
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pain ratings from T0 to T1 is within or outside the range of
the difference in pain ratings between the NRS and VAS
ratings.
According to the literature, the differences between
NRS and VAS means were |0.52| cm for the initial assess-
ment and |0.86| cm across all assessments in a study
conducted among teenagers (mean age 14.7±3.1 years).
Moreover, in this study, the differences between NRS
and VAS ratings decreased with increasing pain severity
across all assessments.34 In another study conducted with
adults, the differences between NRS and VAS ranged
between |2.30| cm and |1.30| cm.34
In our study, the difference between the telephone inter-
view (T0) and the baseline assessment (T1) was 60.3±13.3
and 38.1±21.7 representing a change of 36.8% and a distance
of |22.2| mm or |2.22| cm between the NRS at T0 and the VAS
at T1. According to the data on children provided by Myrvik
(2015) this difference of 2.22 cm would be outside the range
of differences between the two scales, but within the range
according to the data provided Holdgate (2003), even though
at the outer limit of the interval.
In conclusion, the fact that the pain ratings measured with
the NRS tend to be higher than those measured with the VAS
and the fact that the NRS was used at T0 might have con-
tributed to systematically higher pain ratings at T0 in this
study. It may have thus contributed to larger decreases in pain
ratings from T0 to T1.
34 However, since we expected regres-
sion to the mean to play a role in this analysis, our statistical
approach already controls for the dependency of the differ-
ences between T0 and T1 on the initial values at T0. In our
ANOVAmodel, the initial values were used as covariate, and
thus, the influence of the initial values on the total effect is
extracted. Indeed, there is a significant effect of the covariate
(pain rating NRS at T0), nonetheless, the factor days between
T0 and T1 remained significant and thus non-neglectible. It is
impossible to estimate how much of the difference between
NRS and VAS contributed to the effect of the increased initial
values (pain ratings at T0); however, the ANCOVA reveals a
significant effect of waiting time beyond a significant effect
of the covariate. Thus, even though the initial values at T0
played an important role for the total effect, there still
remains substantial support for a decrease in pain ratings
during the waiting time between recruitment and inclusion.
Further directions and recommendations
The Hawthorne effect predicts that a certain reduction in pain
has to be expected simply due to the fact that patients parti-
cipate in a study. Consequently, inclusion criteria should
possibly be strict, eg, pain intensity >60. There are several
challenges related to this: i) The total available study popula-
tion will be significantly smaller and consequently, recruit-
ment may be more difficult; ii) Such a high pain intensity
may not reflect the majority of the patients and will thus
restrict the generalization of the study results (external valid-
ity); iii) A high pain rating as inclusion criterion will also
make the main outcome more vulnerable to distribution-
related phenomena, such as regression to the mean.
While the Hawthorne effect is uncontrollable, the
impact of the natural course of the disease could be con-
trolled by keeping the time frame as tight as possible. In
our study on neck pain, the main reduction in pain inten-
sity occurred within 2 weeks and thus a time frame of a
few days would be more advisable.
However, another methodological approach to the nat-
ural course of the disease and regression to the mean could
be to wait more than 14 days in order to avoid the initial
fluctuations in pain ratings (see Figures 3 and 4 where six
study participants already show an increase in pain ratings
over time). The benefits of such a design would be that it
is easier to pick up a defined treatment effect while the
disadvantages are that the study population may not repre-
sent typical pain patients.
Moreover, the main outcome measure of a study, in this
case the pain intensity, should be recorded systematically
after the first contact (eg, telephone interview) throughout
the recruitment and enrolment. This allows for better doc-
umentation of symptom changes over time. Another pos-
sibility would be to conduct an observational pilot study
before an interventional trial to observe the natural course
of the disease in the target group. Such data would allow
for a more systematic recruitment approach since a popu-
lation-derived inclusion criterion, information about the
time course of the symptom, and the recruitable patient
population would be available.
Conclusion
Three main potential influences on a clinically relevant
decrease in pain scores during the enrolment phase of a
study were identified; the natural course of the disease,
regression to the mean, and the Hawthorne effect. They
can all impose a threat to a clinical trial of diseases with a
fluctuating symptom pattern because they are difficult to
control. Clinical trial methodology, by defining a primary
inclusion criterion related to the primary outcome mea-
sure, comprises a risk of a regression to the mean in
spontaneously fluctuating diseases. Awareness of this
Dovepress Nothnagel et al
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phenomenon can contribute to better routines for clinical
studies accounting for a change in the main outcome
measure during enrolment and recruitment.
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